marketcap
Facebook
Twitter
Telegram
Report an ErrorAnnual report 2024
added 11-26-2024
Arrowhead Pharmaceuticals Balance Sheet 2011-2024 | ARWR
Annual Balance Sheet Arrowhead Pharmaceuticals
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
14.7 M | 4.28 M | -26.4 M | -159 M | - | -222 M | -27.8 M | -22.3 M | -82.6 M | -80.5 M | -131 M | -18.1 M | -1.04 M | -6.9 M |
Long Term Debt |
111 M | 105 M | 78.8 M | 23.3 M | - | - | 2.1 M | 2.33 M | 2.53 M | - | - | 50 K | 839 K | 607 K |
Long Term Debt Current |
6.34 M | 10.6 M | 2.78 M | 2.25 M | 1.09 M | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
846 M | 373 M | 135 M | 155 M | 20 M | 8.74 M | 4 M | 4.45 M | 7.51 M | 6.75 M | 4.98 M | 2.87 M | 2.39 M | 742 K |
Total Current Liabilities |
103 M | 105 M | 139 M | 147 M | 40.7 M | 97.1 M | 12.4 M | 18.7 M | 25.6 M | 15.9 M | 11.8 M | 8.73 M | 5.33 M | 2.58 M |
Total Liabilities |
- | - | - | - | - | 106 M | 16.4 M | 23.2 M | 33.2 M | 22.6 M | 16.8 M | 11.6 M | 7.72 M | 3.32 M |
Deferred Revenue |
- | 866 K | 74.1 M | 111 M | 19.3 M | 77.8 M | 600 | 5.27 M | 2.57 M | 103 K | 103 K | 103 K | 37.5 K | - |
Retained Earnings |
-1.63 B | -1.03 B | -821 M | -645 M | -504 M | -419 M | -487 M | -433 M | -398 M | -317 M | -225 M | -166 M | -135 M | -114 M |
Total Assets |
1.14 B | 766 M | 692 M | 710 M | 523 M | 350 M | 112 M | 104 M | 128 M | 132 M | 183 M | 37.3 M | 16.5 M | 15.9 M |
Cash and Cash Equivalents |
103 M | 111 M | 108 M | 184 M | 144 M | 222 M | 30.1 M | 24.8 M | 85.4 M | 81.2 M | 133 M | 19.1 M | 3.38 M | 7.51 M |
Book Value |
1.14 B | 766 M | 692 M | 710 M | 523 M | 244 M | 95.2 M | 80.9 M | 95 M | 110 M | 166 M | 25.7 M | 8.81 M | 12.6 M |
Total Shareholders Equity |
185 M | 271 M | 418 M | 409 M | 462 M | 245 M | 95.8 M | 81.4 M | 95.6 M | 110 M | 167 M | 27.5 M | 10 M | 12.8 M |
All numbers in USD currency
Quarterly Balance Sheet Arrowhead Pharmaceuticals
| 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
112 M | 114 M | 115 M | 105 M | 79.9 M | 80.1 M | 79.5 M | 78.8 M | - | 22.7 M | 22.5 M | 23.3 M | 22.9 M | 23.3 M | 19.7 M | 20 M | 20 M | 20 M | 14.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
448 M | 395 M | 389 M | 373 M | 344 M | 339 M | 373 M | 135 M | - | 112 M | 129 M | 155 M | 103 M | 155 M | 19.7 M | 20 M | 20 M | 20 M | 14.4 M | 8.74 M | 8.74 M | 8.74 M | 34.8 M | 4 M | 4 M | 4 M | 4.3 M | 4.45 M | 4.45 M | 4.45 M | 10.1 M | 7.51 M | 7.51 M | 7.51 M | 6.68 M | 6.75 M | 6.75 M | 6.75 M | 4.93 M | 4.98 M | 4.98 M | 4.98 M | 2.76 M | 2.87 M | 2.87 M | 2.87 M | 1.55 M | 2.39 M | 2.39 M | 2.39 M | 2.25 M | 742 K | 742 K | 742 K |
Total Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | 866 K | 16.9 M | 29.8 M | 66.3 M | 74.1 M | - | 97.9 M | 109 M | 111 M | 151 M | 111 M | 6.74 M | 19.3 M | 19.3 M | 19.3 M | 54 M | 77.8 M | 77.8 M | 77.8 M | 125 M | 600 | 943 K | 1.56 M | 1.88 M | 5.27 M | 5.27 M | 5.27 M | 25.6 M | 2.57 M | 2.57 M | 2.57 M | 109 K | 103 K | 103 K | 103 K | 109 K | 103 K | 103 K | 103 K | 109 K | 103 K | 103 K | 103 K | 109 K | 37.5 K | 37.5 K | 37.5 K | 101 K | - | - | - |
Retained Earnings |
-1.45 B | -1.28 B | -1.16 B | -1.03 B | -916 M | -813 M | -862 M | -821 M | - | -663 M | -708 M | -645 M | -581 M | -645 M | -525 M | -504 M | -504 M | -504 M | -422 M | -419 M | -419 M | -419 M | -475 M | -487 M | -487 M | -487 M | -446 M | -433 M | -433 M | -433 M | -411 M | -398 M | -398 M | -398 M | -336 M | -317 M | -317 M | -317 M | -247 M | -225 M | -225 M | -225 M | -177 M | -166 M | -166 M | -166 M | -140 M | -135 M | -135 M | -135 M | -116 M | -114 M | -114 M | -114 M |
Total Assets |
884 M | 955 M | 626 M | 766 M | 796 M | 891 M | 891 M | 692 M | - | 704 M | 639 M | 710 M | 735 M | 710 M | 499 M | 523 M | 523 M | 523 M | 588 M | 350 M | 350 M | 350 M | 341 M | 112 M | 112 M | 112 M | 88.2 M | 104 M | 104 M | 104 M | 144 M | 128 M | 128 M | 128 M | 111 M | 132 M | 132 M | 132 M | 162 M | 183 M | 183 M | 183 M | 92.7 M | 37.3 M | 37.3 M | 37.3 M | 15.2 M | 16.5 M | 16.5 M | 16.5 M | 23.1 M | 15.9 M | 15.9 M | 15.9 M |
Cash and Cash Equivalents |
69.4 M | 128 M | 58.2 M | 111 M | 105 M | 135 M | 202 M | 108 M | - | 86.4 M | 91.6 M | 184 M | 326 M | 184 M | 140 M | 144 M | 144 M | 144 M | 461 M | 222 M | 222 M | 222 M | 190 M | 30.1 M | 30.1 M | 30.1 M | 11.5 M | 24.8 M | 24.8 M | 11.5 M | 102 M | 85.4 M | 85.4 M | 102 M | 62.2 M | 81.2 M | 81.2 M | 62.2 M | 104 M | 133 M | 133 M | 104 M | 59.7 M | 19.1 M | 19.1 M | 59.7 M | 2.93 M | 3.38 M | 3.38 M | 2.93 M | 6.77 M | 7.51 M | 7.51 M | 6.77 M |
Book Value |
884 M | 955 M | 626 M | 766 M | 796 M | 891 M | 891 M | 692 M | - | 704 M | 639 M | 710 M | 735 M | 710 M | 499 M | 523 M | 523 M | 523 M | 588 M | 350 M | 350 M | 350 M | 341 M | 112 M | 112 M | 112 M | 88.2 M | 104 M | 104 M | 104 M | 144 M | 128 M | 128 M | 128 M | 111 M | 132 M | 132 M | 132 M | 162 M | 183 M | 183 M | 183 M | 92.7 M | 37.3 M | 37.3 M | 37.3 M | 15.2 M | 16.5 M | 16.5 M | 16.5 M | 23.1 M | 15.9 M | 15.9 M | 15.9 M |
Total Shareholders Equity |
331 M | 484 M | 160 M | 271 M | 382 M | 465 M | 396 M | 399 M | 474 M | 452 M | 373 M | 409 M | 437 M | 373 M | 454 M | 462 M | 493 M | 494 M | 500 M | 245 M | 245 M | 245 M | 172 M | 95.8 M | 95.8 M | 95.8 M | 70.8 M | 81.4 M | 81.4 M | 81.4 M | 97.8 M | 95.6 M | 95.6 M | 95.6 M | 92.9 M | 110 M | 110 M | 110 M | 146 M | 167 M | 167 M | 167 M | 82.7 M | 27.5 M | 27.5 M | 27.5 M | 8.97 M | 10 M | 10 M | 10 M | 16.2 M | 12.8 M | 12.8 M | 12.8 M |
All numbers in USD currency